The Kennel Club Genetics Centre at the Animal Health Trust has identified a genetic mutation which causes progressive retinal atrophy (PRA) in Golden Retrievers, and developed a DNA test to identify carriers.

PRA is a retinal disease which causes loss of vision and leads to blindness. PRA cannot be treated - the most successful way to combat the inherited condition is to identify dogs that carry the mutation and develop informed breeding strategies.

The new DNA test has been developed following the identification of the mutation which causes the most common form of PRA among Golden Retrievers in Europe - known as GR_PRA1. The mutation which causes a second form of PRA is still to be identified.

Cathryn Mellersh, Head of Canine Genetics at the AHT, said: "Our research shows that this mutation is present in the UK Golden Retriever population, so it's likely that several hundred new carriers are being born each year and that Golden Retrievers are invariably going blind as a result.

"This new DNA test will enable breeders to learn whether their dogs are carriers of the mutation. This, in turn, will enable them to make better informed breeding decisions and therefore produce puppies which will not go blind as a result of this mutation."

Mike Townsend, Chairman of the Kennel Club Charitable Trust, said: "This is a real breakthrough and one which we hope will help to prevent blindness in many Golden Retrievers in the years to come. Every dog deserves to lead a healthy, happy life and it is important that we do all we can to ensure that future generations are given this opportunity. Our knowledge about inherited diseases in dogs is growing every day and the development of DNA tests such as this one allows breeders to ensure that the healthiest genes are passed down through the generations."

The DNA test for PRA follows the success of the AHT's DNA test launched last year to identify carriers of a mutation that causes primary lens luxation. This test identifies carriers in more than 12 breeds of dog, including Miniature Bull Terriers, Jack Russell Terriers, Parson Russell Terriers and Patterdale Terriers. To date more than 6,500 samples from 36 countries have been tested.

The Kennel Club Charitable Trust has committed £1.2 million to the Kennel Club Genetics Centre at the AHT, which will undertake research into approximately 25 inherited diseases over the next five years, facilitating the creation of further diagnostic tests which will improve the health and welfare of generations of dogs.

Full information on the Golden Retrievers PRA DNA test, and information on ordering sample kits, will be available from http://www.aht.org.uk/ from 15 November.

Medivet has announced the appointment of John Bower MBE BVSc MRCVS to its Panel of Enquiry set up following coverage of the company on Panorama.

Mr Bower has been President of the British Veterinary Association, the British Small Animal Veterinary Association, and the Veterinary Practice Management Association.

Mr Bower said: "Medivet is a large partnership with numerous branches and I am looking forward to helping the partners assess and review the management of their practice to eliminate the sort of incidents and situations that were alleged in the Panorama programme.  This panel will look deeply into the management and I have been convinced by the partners that they are determined to take appropriate measures where necessary."

Adi Nell, Medivet central partner and fellow member of the panel said: "We are delighted that John Bower is to be a part of our panel. John is not only an eminent vet of unquestionable ethical standing, but he set up and ran a medium-sized veterinary partnership for 38 years. His expertise will be crucial to Medivet, as the panel carries out its investigations and makes its recommendations over the next few months."

Mr Bower, who retired from general practice in 2007, is currently Veterinary Advisor to Petplan Insurance Company and a trustee of two national charities - Hearing Dogs for Deaf People and The Petplan Charitable Trust. Mr Bower was awarded the BSAVA Melton Award for meritorious contributions to Small Animal Practice in 1991, the MBE in 2010 for services to the BVA:AWF, and has authored or co-authored a number of books including Veterinary Practice Management, The Dog Owner's Veterinary Handbook and The Cat Owner's Veterinary Handbook.

Intervet/Schering-Plough Animal Health has launched the Intestinal Health Center for Poultry website (www.ihc-poultry.com), a website to keep producers, veterinarians, nutritionists, academics and students informed about this aspect of poultry production.

The company says it has published a wealth of practical, science-driven information and ideas to help producers manage costly gut diseases more effectively through vaccination, nutrition, sanitation and prudent drug use.

Marcelo Lang, global marketing director for the company's Poultry Business Unit said: "The new website lets you find virtually anything you need, quickly and easily, on specific intestinal health topics and products".

The website also offers a library of past issues of the company's Intestinal Health magazine and its predecessor, CocciForum, as well as three newsletters - Broiler Health, Layer Health and Turkey Health. In addition, the website includes an interactive feature called "Gut Reactions," where visitors can answer a frequently updated questionnaire related to intestinal health, immediately view survey results and then access links with more information on that topic. There is also a product finder to help users find Intervet/Schering-Plough Animal Health intestinal health products available in their market.

Marcelo added: "The Intestinal Health Center for Poultry is another example of Intervet/Schering-Plough Animal Health's commitment to educating the industry about this increasingly important segment of poultry health. We look forward to getting feedback on the site so that we can make it even better."

The Pet Doctors Group has announced that it will continue its New Graduate Programme for Autumn 2010, an initiative which the company says has proved successful since its launch in 2008. The aim of the scheme is to appoint new graduates to work in a selected number of its practices, spread across the South East of England.

Brodie Collins, Area Manager at Pet Doctors, will be meeting final year students at the Bristol University School of Veterinary Science, the Royal Veterinary College in London and the University of Cambridge Veterinary School during February and March 2010 to promote the scheme and explain the firm's approach to supporting graduates during their critical first year in practice. Successful applicants will be shortlisted by August 2010 with appointments made by September.

With the economic climate causing many practices to postpone recruitment or reduce support and training for new qualified graduates, competition for places on schemes such as this is expected to be high this year.

Brodie said: "The first twelve months out of vet school can be the most daunting of a vet's career. They're suddenly thrust into a public facing role with little experience of communicating with clients or making a diagnosis. Many have limited surgical experience and even fewer have business acumen. They really need structured support and training to build their confidence and enable them to perform effectively both from a clinical and a business perspective. Mentoring is a key support tool so our graduates are all placed with practices where this can be provided regularly.

Feedback from our scheme last year showed that what the graduates we recruited most valued was working within a team which encouraged them to be open and honest so that they could readily ask for advice and help when they needed it.  We're all individuals and perform much better if we feel comfortable with the people we're working with.  Our scheme enables us to build on our graduates'  strengths and support them in areas which they find more challenging.

We provide clinical and surgical training but also focus on the development of communication and management skills to help graduates fulfil their role as part of a business team.  The graduates we appoint will each spend their first year based within one of our smaller practices, working as part of a small and closely knit team.  At the end of the first year, if all is going well, they will have the option to stay on and help grow that practice.

In addition to veterinary skills, we're looking for graduates with a good personality fit, a strong work ethic, a caring approach and ideally some level of business understanding."

For further information on the scheme, please contact Brodie at Brodie@petdoctors.co.uk

Genitrix is encouraging practices to capitalise on the growing market opportunity for dental treatments by offering a free pack of its Dentagen Dental Wax and a special offer of six products for the price of five for the rest of its Dentagen dental range during March 2010. 

The company is also urging practices to declare March 'Dental Care Month' and to use it as a platform to step up the education they offer to pet owners on this important welfare issue.

According to Genitrix, the Dentagen range uses a plant extract called RF2 which operates as an 'anti-biofilm' treatment, modifying the membrane of oral bacteria to prevent them from producing plaque even at low concentrations. Dentagen Wax is applied to dogs or cats at the end of dental procedures in practice, while the animal is still sedated. It forms a protective coating over the teeth, which lasts for several days.

Each pack of wax contains five syringes enabling practices to offer free wax applications to pets during Dental Care Month. Pet owners can then maintain the protective coating by giving their pet either Dentagen plaque prevention chews every other day or the Dentagen Aqua drinking water additive.

For dogs, the chews are supplied in two sizes with the larger size designed for dogs over 8 kg and a smaller size for dogs less than 8 kg. Dentagen Aqua is a drinking water additive containing RF2. The company says the palatable liquid, which is added to a pet's drinking water, has proved particularly effective in treating cats which don't respond well to tooth-brushing or dental chews.

Rob Watkins, Genitrix' marketing director said: "It's well known that dental disease affects 80% of pets over three years' old and, if left untreated, can go on to cause serious health problems.  

"Data from veterinary practices also confirms that many of them are not achieving the revenue they could from offering dental treatments to their clients. We want them to get their teeth into this important revenue opportunity so we're calling on practices to make March 'Dental Care Month' and are offering them a special deal on Dentagen products to get them started.

"The efficacy of the Dentagen range in inhibiting plaque formation has been proven in clinical trials and it has proved popular with pet owners, increasing their compliance with preventative health regimes."

To order your free pack of Dentagen Wax and to take advantage of the special offer on the rest of the range, contact Genitrix on 01403 786345 or by email at mail@genitrix.co.uk

The Disciplinary Committee of the Royal College of Veterinary Surgeons has directed that the name of a veterinary surgeon who had been practising in Essex be removed from the RCVS Register, having found him guilty of attempting to obtain medicines dishonestly.

James Alexander Lockyear, a graduate from Pretoria University in South Africa, was charged with two offences. The case was heard in his absence, although the Committee did not draw any adverse inference from this. One charge concerned his attempted purchase of steroids from a pharmacy in Colchester by dishonestly representing that the medicine was for legitimate veterinary use. The second charge related to several instances of what the Committee referred to as "inappropriate and unprofessional behaviour", including showing an offensive image to another staff member on a mobile phone, placing the testicle of a castrated dog in his mouth and the misuse of an endotracheal tube.

All of the incidents had taken place between April 2008 and September 2009, while Mr Lockyear was practising as a locum veterinary surgeon at St Runwald's Veterinary Surgery, Colchester, Essex.

The Disciplinary Committee heard evidence from a pharmacist, Mr Noble, to whom Mr Lockyear had presented an incomplete veterinary prescription for 12 ampoules of Sustanon, a prescription-only anabolic steroid for humans, and a further pharmacist, Mr Foskett MRPharmS, who outlined his suspicions that the steroids were in fact for Mr Lockyear's personal use (Sustanon is a substance which can potentially be misused in relation to body-building). Mr Lockyear had originally claimed the drugs were for general stock at the practice; he later returned with a second prescription, for double the amount of Sustanon, claiming it was for his own dog; later again, he said the prescription was for a friend's dog.

The Committee also heard evidence from the veterinary owner of the practice, a veterinary nurse and a student veterinary nurse working in the practice team, and from Dr Maddison MRCVS, an expert on small animal clinical pharmacology. Dr Maddison informed the Committee that there was a veterinary alternative to Sustanon, so it was not necessary for that drug to have been sought by Mr Lockyear. She was also of the view that Sustanon would not have been suitable to treat the ailments for which Mr Lockyear claimed it was to be used.

The Committee found Mr Lockyear guilty of the first charge - that is attempting to obtain medicines dishonestly. Chairing the Disciplinary Committee, Mrs Alison Bruce, said: "Whilst it was a one-off incident, it is conduct which falls far short of that which is expected of a member of the profession. It involves serious dishonesty; it represents an abuse of a veterinary surgeon's authority to prescribe drugs; it is conduct which tends to undermine public trust in the profession, and the honesty of its members; it is conduct which compromised other professionals, the pharmacists involved, and undermined the trust which ought to exist between pharmacists and veterinary surgeons generally, in the important area of drug prescription." The Committee therefore directed that Mr Lockyear's name be removed from the Register.

Regarding the second charge, the Committee was most concerned about the incident relating to the dog's testicles, which it felt offended against Mr Lockyear's duty to treat with respect all animals which were his patients. Taking the three incidents as a whole, the Committee felt that Mr Lockyear should be seriously criticised for behaviour that was "unprofessional... juvenile, inappropriate, disgusting and offensive". However, they felt that the conduct was not malicious, and did not occur in the presence of a member of the public, so concluded that this did not amount to disgraceful conduct in a professional respect.

Ridgeway Research Ltd has a surplus supply of short-dated Target IgG kits on special offer.

The kits are to test for passive transfer to foals via colostrum. Each kit contains 20 tests and normally costs £74. They have been reduced to £20 to clear. The use by date is end February 2010.

If you are interested, please email jo@ridgewayresearch.co.uk, or ring 01594 530809 for further information.

The Disciplinary Committee of the Royal College of Veterinary Surgeons last week decided that a Lincolnshire-based veterinary surgeon should not be restored to the RCVS Register, having previously struck him off for disgraceful professional conduct, as it was not convinced that he accepted the seriousness of its finding.

In October 2007, Robert Morris, of Brant Broughton, near Lincoln, was removed from the Register having been found guilty of falsely certifying a horse to be fit for sale, despite knowing that it had a respiratory problem that could prejudice its use in the future by its new owners.

At the hearing, which concluded on 7 January, the Disciplinary Committee focused on several areas. On the day following the Committee's decision in October 2007, Mr Morris had falsely certified that two horses had been fully vaccinated every six months by his practice, when he did not know that this was the case. On two occasions during September and October of 2009, he had held himself out to be a veterinary surgeon, including examining, diagnosing and treating animals (horses and dogs). These issues, together with the fact that Mr Morris told the Committee that he was not fully familiar with the Twelve Principles of Certification, as set out in the RCVS Guide to Professional Conduct, led the Committee to believe that Mr Morris did not understand the seriousness of his conviction for disgraceful professional conduct.

The Committee also felt that there was a risk to future welfare of animals and protection of the public arising from Mr Morris' failure to understand the importance of certification. That he remained unfamiliar with the veterinary medicines regulations (and had been convicted at Grantham Magistrates Court on 1 November 2007 for possession of unauthorised veterinary medicinal products on 7 March 2006), was also taken as relevant in this regard.

The Committee also took into account the fact that Mr Morris had undertaken only limited continuing professional development since his removal, and it was concerned that it had not been presented with sufficient evidence to confirm Mr Morris' assertion that he no longer suffers from an alcohol problem.

Chairing the Disciplinary Committee, Mrs Alison Bruce, said: "In the light of its finding that Mr Morris does not fully understand the importance of accurate certification, nor of practising as a veterinary surgeon when he was not entitled to do so, the Committee considers that there is a risk to the future welfare of animals in the event of his name being restored to the Register."

She went on to add that in the case of veterinary surgeons continuing to work in a practice when struck off: "It is fully appreciated that veterinary practices may be owned and managed by lay people, however there must be a clear distinction between managing or working within a veterinary practice and practising veterinary medicine. It is of particular importance that any member who has been removed should recognise the difference between these activities. A member who has been removed must refrain from examining animals, making diagnoses or performing treatments, even under the direction of another veterinary surgeon, this includes giving veterinary advice."

European veterinary practitioners are to receive guidance on the appropriate use of the fluoroquinolone group of antibiotics in treating a wide range of common diseases in companion animals.

The advice has been drawn up by the REQUEST team, a multinational and multidisciplinary group of experts which met for the third time last November. Their recommendations have been designed to help ensure the continued availability of this class of antibiotics in both veterinary and human medicine.

The REQUEST initiative aims to achieve a consensus on when and how to prescribe fluoroquinolones, based on a detailed assessment of published scientific data by its panel of nine acknowledged international experts. Following earlier meetings in Lyon and Vienna they have reached a stage in this ongoing project in which they can offer specific guidance on the use of fluoroquinolones in treating three important conditions in dogs: pyoderma, bacterial diseases of the upper respiratory tract and lower urinary tract infections. They will also be offering guidance on the appropriate use of this class of antibiotics in cats to avoid the development of retinal toxicities, which may occasionally result from treatment with one particular fluoroquinolone drug, enrofloxacin.

The guidance will be presented in papers to be submitted to those scientific journals which will be easily accessible to veterinary practitioners throughout Europe. Further papers will be produced and translated into the main European languages giving guidance on fluoroquinolones use in other important bacterial conditions in dogs and cats.

In the later stages of the project, the team will be highlighting priorities for future research and will use its influence to encourage collaborative studies involving the animal health industry, practitioners, veterinary schools and other research institutions, which will validate and redefine the current recommendations. They will also advise on studies which may provide the information needed in those clinical areas where there is currently insufficient published data on which to base any practical advice, such as the use of fluoroquinolones in minor companion animal species.

The REQUEST initiative is supported by Vetoquinol, a global supplier of fluoroquinolone medicines to the veterinary community. Further support is provided by the healthcare consultancy StratAdviser Ltd, which gives assistance on methodology and other scientific matters and also guarantees the independence of the expert group.

Dorwest Herbs has highlighted research that suggests a highly rational mode of action for kelp seaweed as an aid in the treatment of obesity when used alongside a weight reduction diet. The company is asking vets and nurses to look at the evidence and consider using licensed herbal medicines to help cats and dogs lose weight naturally. To help you evaluate the product, Dorwest is giving away 50 trial packs of Kelp Seaweed Tablets.

Mary Boughton MBE, Quality Director at Dorwest Herbs and the UK's leading specialist in the formulation of veterinary herbal medicines said: "We have lots of evidence that Kelp Seaweed Tablets work as an aid in the treatment of obesity but traditional explanations were based on the effect of iodine supplementation on thyroid function as a mode of action. That just didn't hold water for us. However, in common with many conventional medicines, the mechanisms for mode of action of herbal medicines are often not known. So, it was with some excitement that we heard of research that demonstrated that fucoxanthin, a pigment found in kelp, upregulates expression of UCP1 (uncoupling protein) and produces weight loss in the same region as conventional anti-obesity drugs."

Various studies estimate pet obesity may affect 30 to 60 per cent of pets in the UK and arthritis, heart disease and diabetes are just some of the diseases that occur with increasing frequency in obese pets. The research indicates that fucoxanthin has an effect on glucose metabolism and may lower the risk of coronary heart disease in humans. Phlorotannins found in brown seaweed have also recently been indentified as interfering with both the onset and consequences of osteoarthritis. Mary Boughton points out that multiple effects are often seen when herbal treatments are used, "Herbal treatments contain thousands of plant derived chemical compounds and are known for their diverse action, as opposed to the 'magic bullet' effect seen with conventional medicines. In a condition such as obesity where we see many disruptions of normal metabolism and several co-morbid conditions, choosing a herbal treatment makes sense. Kelp Seaweed Tablets are the logical alternative."

Dorwest has prepared a fully referenced technical information sheet detailing recent scientific studies and data from herbal formularies with reference to the role of kelp seaweed in obesity management.

To help vets and nurses further evaluate Kelp Seaweed Tablets - a licensed herbal medicine - used as part of a weight management programme the company is giving away 50 FREE trial packs containing seven weeks of Kelp Seaweed Tablets for a large breed dog, a case report sheet and the technical information sheet. There is also a prize of £100 of John Lewis shopping vouchers for the most informative case report received before the end of February 2010.  There is one pack available per practice, while stocks last.

To request a technical information sheet or pack call Dorwest Herbs on 01308 897272.

The University of Glasgow Small Animal Hospital has completed a £15 million pound development, including the installation of state-of-the-art diagnostic imaging equipment from Siemens Healthcare.

A Magnetom Essenza MRI, a Somatom Spirit CT and Multix Top analogue X-ray are now in place to assist the examination of animals and to diagnose conditions quickly and accurately. A further order for an Oncor Impression linear accelerator has been placed to enable the hospital to provide cost effective and flexible radiotherapy for its animal patients. 

The Essenza 1.5T MRI scanner replaces a visiting mobile MRI to provide onsite imaging. According to Siemens, the Essenza is able to give a high level of diagnostic information in just one examination. With rapid and high quality imaging, animal patients spend less time under anaesthetic and the time taken to begin treatment can be reduced. 

The installation of the Somatom Spirit CT scanner allows the hospital to look beyond bone structure and into soft tissue and organ imaging. Siemens says the speed and versatility of the Spirit are ideal for veterinary CT. Alongside the Spirit, the hospital has also installed a Multix Top analogue X-ray system providing the hospital with a simple and efficient imaging tool. 

Calum Paterson, Hospital Manager at Glasgow Small Animal Hospital said: "By advancing our scanning facilities we are able to increase the services we offer and provide rapid, high-resolution images for our patients. The Siemens scanners are highly suitable in terms of their size and design to be able to accommodate all the small animal patients we see."

James Weir, Regional Sales Manager at Siemens Healthcare said: "Siemens technology is designed to speed up diagnosis by providing faster examination times and high quality imaging. These key functions provide excellent quality of care to any patient, be it human or animal.  The installations are transforming veterinary care by providing enhanced diagnosis and improving treatment pathways for domestic pets."

Janssen Animal Health has announced that it has acquired the distribution rights for a range of sedatives and anaesthetics for small and large animals, including Dexdomitor, Domitor and Antisedan.

Janssen aquired the marketing and distribution rights, which were previously held by Pfizer Inc, from Orion Corporation.

Dr. Enno Gottschalk , Janssen's European Director Marketing and Sales said: "This acquisition of distribution rights results in the perfect combination of proven and effective products with the outstanding service and technical selling capabilities of Janssen Animal Health. The products include the sedative Dexdomitor and Domitor, as well as the antagonist Antisedan. Among large animals, predominantly horses, the sedative injection Domosedan is now on offer as part of the Janssen Animal Health portfolio."

A research project funded by equine charity The Horse Trust has succeeded in killing equine sarcoid cells in vitro by silencing a gene in the virus that causes sarcoids. The researchers are now hoping to obtain funding for clinical trials using the new technique, which could result in a more effective, non-toxic treatment for sarcoids.

Sarcoids are skin tumors caused by infection with the Bovine Papillomavirus (BPV). They are the most common type of tumour found in horses - the estimated prevalence in the UK is 6-7%. Although the disease is rarely life threatening, many horses with sarcoids are euthanased because the condition is untreatable or because the horse is unsellable. Currently there is no universally effective treatment for sarcoids and if treatment fails the sarcoids will often come back worse.

However, research that was given funding by The Horse Trust offers a potential ray of hope for owners of horses affected by sarcoids. The research was published in Virus Research journal earlier this year.

The research, which was led by Professor Lubna Nasir of the University of Glasgow, found that by inhibiting the activity of a particular viral protein within sarcoid cells, the amount of viral DNA in the cells reduced. This led to a reduction in the growth of the sarcoid cells and caused the cell to die by Programmed cell-death (PCD). The researchers believe that PCD occurs because the sarcoid cells become reliant on the virus.

Professor Nasir said: "This could potentially be a major breakthrough in the treatment of sarcoids. We are now seeking funding to use this technique in clinical trials on horses that have sarcoids."

The research team inhibited the activity of a viral protein called E2, which is needed by BPV to replicate. They used a novel approach termed 'gene silencing' to suppress the activity of the gene that codes the E2 protein. The research was carried out in vitro on fibroblast cells, which had been cultured from sarcoid tissue removed from animals during surgery.

As this research was carried out in vitro, the researchers will now need to see if they can replicate the results in vivo, by developing a way of targeting the sarcoid cells in horses.

"One of the challenges with gene silencing is administering it within clinical setting - as you need to get molecules into every cell. As sarcoids are on the surface of a horse, we think administration should be relatively easy - potentially by injecting or applying a cream to the sarcoid," said Professor Nasir. "If we are able to successfully develop this technique it would be a non-toxic and easy to administer treatment for horses affected by this distressing condition."

Nasir's research could also have an impact on the treatment of lesions in cattle, which are also caused by BPV. Around 50% of cattle in the UK are estimated to have lesions. It may also help with the treatment of Human Papillomavirus (HPV) infections in humans. HPV, which is similar to BPV, can lead to various cancers in humans including cervical and vaginal cancer.

Paul Jepson, Chief Executive and Veterinary Director of The Horse Trust said: "We are really excited that the research we have funded could lead to a major breakthrough in the treatment of sarcoids."